Annexon Biosciences is a biopharma company developing complement pathway inhibitors for the treatment of neurodegenerative and autoimmune diseases.
Annexon was co-founded by Ben Barres, Prof and Chair of Neurobiology at Stanford University School of Medicine, and Arnon Rosenthal, Co-founder and CEO of Alector, and Co-founder, former President and CSO of Rinat Neurosciences.
No review box found! Insert a valid box ID.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/annexon-biosciences” connections=”true” suffix=””]
June 2016, Annexon raised $44 million Series B funding led by New Enterprise Associates and included participation by Correlation Ventures. Existing investors Novartis Venture Fund, Clarus and Satter Investment Management LLC also were involved.
In Dec 2014, Annexon secured $34 Mn Series A-1 financing, to support development of its lead candidate, ANX005. The round was led by Novartis Venture Funds with participating investors Satter Investment Management, LLC, and Clarus Ventures, LLC.
Recover your password.
A password will be e-mailed to you.